Influential Rheumatoid Factors(5/8/2026)

Rheumatoid factor, long considered a hallmark of rheumatoid arthritis, is emerging as a surprisingly broad biomarker of systemic disease severity—extending far beyond joint inflammation. A new study of psoriatic arthritis patients reveals that seropositivity (16%) correlates with more aggressive disease, worse treatment response, and higher rates of biologic therapy failure. Even more striking, a comprehensive review links rheumatoid factor to increased risks of cardiovascular disease, metabolic syndrome, type 2 diabetes, and liver disease—even in people without rheumatoid arthritis. This challenges the notion that RF is merely a rheumatology-specific marker and suggests it may reflect underlying immune dysregulation or chronic inflammation across organ systems. Meanwhile, real-world data from Taiwan shows tofacitinib and TNF inhibitors have comparable long-term safety and efficacy in new DMARD starts, raising urgent questions about first-line therapy choices—especially now that tofacitinib is generic. The evidence supports switching classes after TNF failure rather than cycling through multiple TNFs, aligning with ULAR 2025 guidelines. On a different note, the podcast delivers a passionate call to action on the looming shortage of rheumatologists, urging clinicians to mentor trainees through ACR-sponsored programs.